Dobutamine
Based on 5 publication(s) in Google Scholar
Dobutamine is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine can increase cardiac output and correct hypoperfusion.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.75%
- No. CAS: 34368-04-2
- Fòrmula: C18H23NO3
- Peso molecular:301.38
-
Almacenamiento:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Neurotransmitter Receptor Compound Library
HY-L062
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Obesity Compound Library
HY-L087
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
Antidepressant Compound Library
HY-L108
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Activators Library
HY-L159
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Dobutamine
More
Customer Validation & Images
-
Apoptosis Analysis
-
Flow Cytometry
-
Flow Cytometry
-
Cell Proliferation/Viability Assay
-
IF
Ver todos los productos específicos de isoformas Adrenergic Receptor
More
Actividad biológica
|
α adrenergic receptor |
β adrenergic receptor |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
4.17 μM
Compound: Dobutamine
|
Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay
Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay
|
[PMID: 28230985] |
| Hepatocyte | IC50 |
3.7 nM
Compound: Dobutamine
|
Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs
Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs
|
[PMID: 18212104] |
Dobutamine (0.15-20 mg/kg; i.p.) results in subsequent increase in the left ventricular function and heart rate acceleration with an increasing dose in wildtype mice[3].
Dobutamine results in significant inotropic, lusitropic, and chronotropic cardiac response with a high dose in wildtype mice[3].
Low doses of Dobutamine significantly increases inotropic and lusitropic cardiac performance without chronotropic changes in the Tgαq*44 mice[3].
Dobutamine increases heart rate only after high doses, but then inotropic and lusitropic cardiac functional reserve is lost[3].
Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Tgαq*44 mice (heart failure models)[3]
-
Dosage:0.15 mg/kg, 0.5 mg/kg as a low dose, 1.5 mg/kg, 5 mg/kg, 20 mg/kg as a high dose
-
Administration:Intraperitoneal injection
-
Result:Induced different response in cardiac function on a low and high dose in mice with with heart failure.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 34368-04-2
-
Appearance Solid
-
Peso molecular 301.38
-
Fòrmula C18H23NO3
-
Color White to off-white
-
SMILES
OC1=CC=C(CCNC(C)CCC2=CC=C(O)C=C2)C=C1O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Anal Chem
2025 Jul 15;97(27):14220-14229. PMID: 40601392 -
Biochem Pharmacol
2025 Nov 29:244:117576. PMID: 41319924 -
Front Cell Dev Biol
2022 Apr 20;10:889656. PMID: 35517499
Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]
Dobutamine hydrochloride (dobutamine; 10 μM; 18 h; 10 Gy IR) decreased IR-induced cell apoptosis. Ⅰ: control cells without IR treatment, Ⅱ: control cells with IR treatment, Ⅲ: dobutamine pre-treated control cells with IR treatment, Ⅳ: BRCA1 knock-down cells with IR treatment, Ⅴ: dobutamine pre-treated BRCA1 knock-down cells with IR treatment, Ⅵ: 8-CPT-cAMP pre-treated BRCA1 knock-downcells with IR treatment.
Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]
Dobutamine hydrochloride (dobutamine; 10 μM; 18 h; 10 Gy IR) decreased IR-induced cell apoptosis. Ⅰ: control cells without IR treatment, Ⅱ: control cells with IR treatment, Ⅲ: dobutamine pre-treated control cells with IR treatment, Ⅳ: BRCA1 knock-down cells with IR treatment, Ⅴ: dobutamine pre-treated BRCA1 knock-down cells with IR treatment, Ⅵ: 8-CPT-cAMP pre-treated BRCA1 knock-down cells with IR treatment.
Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]
Dobutamine hydrochloride (dobutamine; 10 μM; 18 h; 10 Gy IR) showed the percentages of G1 cells in IRtreated control and BRCA1 knock-down A2780 cells decreased to 44.32 and 43.03%, respectively, suggesting that cAMP terminated the cell cycle arrest caused by DNA damage. Ⅰ: control cells without IR treatment, Ⅱ: control cells with IR treatment, Ⅲ: dobutamine pre-treated control cells with IR treatment, Ⅳ: BRCA1 knock-down cells with IR treatment, Ⅴ: dobutamine pre-treated BRCA1 knock-down cells with IR treatment, Ⅵ: 8-CPT-cAMP pre-treated BRCA1 knock-down cells with IR treatment.
Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]
Dobutamine hydrochloride (dobutamine; 10 μM) treated BRCA1 knock-down A2780 cells could inhibited the proliferation of the CD8+ T cells.
Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]
Dobutamine hydrochloride (dobutamine; 10 μM; 18 h after IR) showed weaker BAX signals in the IR-irradiated control and BRCA1 knockdown A2780 cells, and 13.7 and 14.5% of cancer cells were BAX positive, respectively.
Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]
Dobutamine hydrochloride (dobutamine; 10 μM; 18 h after IR) decreased the protein expression of BAX and cleaved caspase-3 in the IR-irradiated control and BRCA1 knockdown A2780 cells.
Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]
Dobutamine hydrochloride (dobutamine; 10 μM; 18 h after IR) decreased the protein expression of p53 in the IR-irradiated BRCA1 knockdown A2780 cells.
-
Comput Struct Biotechnol J
Drug repurposing screens to identify potential drugs for chronic kidney disease by targeting prostaglandin E2 receptor. [Abstract]2023 Jul 7:21:3490-3502. PMID: 37484490 -
Environ Toxicol
Phenylacetyl glutamine (PAGln) enhances cardiomyocyte death after myocardial infarction through β1 adrenergic receptor. [Abstract]2024 Mar;39(3):1682-1699. PMID: 38041472
Solvente y solubilidad
DMSO : 100 mg/mL (331.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (16.59 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (16.59 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Tuttle RR, et al. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res. 1975 Jan;36(1):185-96. [Content Brief]
[2]. Vallet B, et al. Dobutamine: mechanisms of action and use in acute cardiovascular pathology. Ann Cardiol Angeiol (Paris). 1991 Jun;40(6):397-402. [Content Brief]
[3]. Tyrankiewicz U , et al. Characterization of the cardiac response to a low and high dose of dobutamine in the mouse model of dilated cardiomyopathy by MRI in vivo. J Magn Reson Imaging. 2013 Mar;37(3):669-77. [Content Brief]
[4]. Tibayan FA, et al. Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):438-44. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3181 mL | 16.5904 mL | 33.1807 mL | 82.9518 mL |
| 5 mM | 0.6636 mL | 3.3181 mL | 6.6361 mL | 16.5904 mL | |
| 10 mM | 0.3318 mL | 1.6590 mL | 3.3181 mL | 8.2952 mL | |
| 15 mM | 0.2212 mL | 1.1060 mL | 2.2120 mL | 5.5301 mL | |
| 20 mM | 0.1659 mL | 0.8295 mL | 1.6590 mL | 4.1476 mL | |
| 25 mM | 0.1327 mL | 0.6636 mL | 1.3272 mL | 3.3181 mL | |
| 30 mM | 0.1106 mL | 0.5530 mL | 1.1060 mL | 2.7651 mL | |
| 40 mM | 0.0830 mL | 0.4148 mL | 0.8295 mL | 2.0738 mL | |
| 50 mM | 0.0664 mL | 0.3318 mL | 0.6636 mL | 1.6590 mL | |
| 60 mM | 0.0553 mL | 0.2765 mL | 0.5530 mL | 1.3825 mL | |
| 80 mM | 0.0415 mL | 0.2074 mL | 0.4148 mL | 1.0369 mL | |
| 100 mM | 0.0332 mL | 0.1659 mL | 0.3318 mL | 0.8295 mL |
Dobutamine Related Classifications
HY-15746A Related Classifications
Powered by Bioz